Article in Infection and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Minna Ding *Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0001-7497-8157
Katrina M Jackson *Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-2944-8015
Madeline Harris-GordonDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Thamotharampillai DileepanDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
David B MeyaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Central Region, Uganda.
Kirsten NielsenDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-2318-168X
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Impact of Cryptococcus Titan Cells on Pathogenesis.R01AI134636 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Kirsten Nielsen · 2018 to 2026
$4.6M
Genomic Research Capacity Building for Cryptococcosis Translational StudiesR01NS118538 · NINDS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Joel Bazira, David Bisagaya Meya · 2020 to 2026
$3.4M
Continuum of Immune Responses to Cryptococcus neoformansR01AI176922 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Kirsten Nielsen · 2023 to 2026
$3.0M
Genomic Research Capacity Building for Cryptococcosis Translational StudiesR21NS108715 · NINDS · UNIVERSITY OF MINNESOTA · PI BAZIRA, JOEL, NIELSEN, KIRSTEN · 2018 to 2019
$352k
The adaptive host response to latent cryptococcosisF30AI155292 · NIAID · UNIVERSITY OF MINNESOTA · PI DING, MINNA · 2021 to 2025
$150k
Single nucleotide variations account for strain specific virulence changes in Cryptococcus neoformansF31AI148047 · NIAID · UNIVERSITY OF MINNESOTA · PI JACKSON, KATRINA M · 2019 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The hypervirulent Type-1/Type-17 phenotype of · full record | OpenQuestion